Ehren K, Meißner A, Jazmati N, et al. - Researchers here examined if and how the Accelerate Pheno system (ADX), a novel technology using fluorescence in situ hybridization for rapid species identification (ID) and morphokinetic bacterial analysis for phenotypic antimicrobial susceptibility testing (AST), affects clinical management and patient outcome. In this quasiexperimental before-and-after observational study, 3 groups with different diagnostic and therapeutic pathways following recent integration of ADX were analyzed: conventional microbiological diagnostics with and without antimicrobial stewardship program (ASP) intervention, and rapid diagnostics (ADX in addition to conventional standard) with ASP intervention. Evaluation of 204 patients was done (conventional diagnostics, n = 64; conventional diagnostics + ASP, n = 68; rapid diagnostics + ASP; n = 72) were evaluated. Outcomes revealed significant reduction in time to ID and AST as well as time to optimal antimicrobial therapy in correlation to using ADX however, the use did not affect antimicrobial consumption and clinical outcome.